Cryoablation plus targeted therapy for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a procedure called cryoablation, which freezes and destroys cancer cells, combined with a targeted therapy drug (anlotinib) for people with advanced bile duct cancer that has not responded to earlier treatments. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed with surgery.
- Your cancer has gotten worse after at least one prior standard treatment (like chemotherapy with gemcitabine and cisplatin plus an immunotherapy).
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are generally well enough to be up and about (ECOG performance status 0–2), and your doctor expects you to live at least 12 more weeks.
- Your blood counts, liver, and kidney function are adequate, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.